Latest Updates

Updated on October 13, 2021

Administration and Safety Module

Special Populations 

  • Pregnant People slides 1.2 – 1.6 updated
  • Guillain-Barré Syndrome new slides 1.19 and 1.20 added 
  • Myocarditis, Pericarditis and Myopericarditis new slides 1.21-1.24 added  
  • FDA: EUA Amendment new slide added 1.11
  • Role of an Additional Dose of COVID-19 Vaccine new slide added 1.13
  • Focus of Clinical Considerations slide new added 1.14   

Anaphylaxis  

  • Observation Period Following Vaccination slide 1.4 updated

Contraindications and Precautions

  •  Observation Period Following Vaccination slide 1.21 updated

Resources

  • MDPH Immunization Division Contact Information slide 1.5 updated

Pfizer Module

  • Comirnaty/Pfizer- BioNTech Vaccine new slides added (2.5 and 2.6)
  • mRNA COVID-19 Vaccines Primary Series new slide added 2.7
  • FDA: EUA Amendment new slide added 2.11
  • CDC ACIP Vote Interim Recommendation new slide added 2.12
  • Focus of Clinical Considerations new slide added 2.13   
  • Moderately and Severely Immunocompromised People new slide 2.14 added
  • Additional Considerations new slide 2.15 added 
  • Implementation Considerations new slide 2.16 added
  • Infection Prevention Measures for Immunocompromised People new slide 2.17 added 
  • New Section 3 Pfizer Booster Doses new slides (3.1-3.10) added

Moderna Module

  • mRNA COVID-19 Vaccines Primary Series new slide added 3.4
  • FDA: EUA Amendment new slide added 3.8
  • CDC ACIP Vote Interim Recommendation new slide added 3.9
  • Focus of Clinical Considerations new slide added 3.10
  • Moderately and Severely Immunocompromised People new slide 3.11 added
  • Additional Considerations new slide 3.12 added 
  • Implementation Considerations new slide 3.13 added
  • Infection Prevention Measures for Immunocompromised People new slide 3.14 added 
  • Myocarditis, Pericarditis and Myopericarditis new slides 3.15 -3.18 added  

Janssen Module 

  • Guillain-Barré Syndrome new slides 3.10 and 3.11 added